The Italian version of the Alzheimer's Disease Assessment Scale (ADAS): psychometric and normative characteristics from a normal aged population

doi:10.1016/0167-4943(94)90022-1

Archives of Gerontology and Geriatrics

Volume 19, Issue 1, July–August 1994, Pages 21-30

https://doi.org/10.1016/0167-4943(94)90022-1 Get rights and content

Abstract

The Alzheimer's Disease Assesment Scale (ADAS) was specifically proposed for the clinical assessment of patients suffering from dementia and is used in different countries. The Italian version of ADAS is presented in this paper together with the description of criteria used in transforming the American edition in the Italian edition. Psychometric and normative data are illustrated and discussed. A sample of 95 healthy volunteers of both sexes ranging in age from 50 to 79 years were recruited from the general population in different parts of Italy and from different social and educational levels. Their performance on the ADAS was analysed by sex, age, and educational level. Results indicated a specific influence of subjects' educational level on the Cognitive Subscale Total Score of ADAS and the need for an adequate correction was evidenced. The two objective measures of memory which constitute, together with the Cognitive Subscale Total Score, the cognitive subscale of ADAS were sensitive to both age and educational level, requiring corrections. The factor structure of the cognitive subscale of ADAS confirms the validity of distinguishing between the clinical-functional scores, which are summarized by the Cognitive Subscale Total Score (CSTS), from those of the objective memory tasks, which are kept separate and used to quantify specific memory characteristics. The main components of the CSTS were 3 factors. The first factor was

References (23)

M. Davidson et al.
4-Aminopyridine in the treatment of Alzheimer's disease
Biol. Psychiatry.
(1988)
M. Fioravanti et al.
Forgetting curves in long-term memory: evidence for a multistage model of retention
Brain Cog.
(1992)
M.F. Folstein et al.
Mini Mental State: a practical method for grading the cognitive state of patients for the clinician
J. Psychiat. Res.
(1975)
E. Hollander et al.
RS86 in the treatment of Alzheimer's disease: cognitive and biological effects
Biol. Psychiatry
(1987)
R. Ihl et al.
Differential validity of psychometric test in dementia of the Alzheimer type
Psychiatry Res.
(1992)
R.E. Becker et al.
Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer's disease: report of an open trial
Drug Dev. Res.
(1990)
R.S. Black et al.
Pentoxifylline in cerebrovascular dementia
J. Am. Geriatr. Soc.
(1992)
E.A. Burch et al.
Comparison of two cognitive rating scales of medically ill patients
Int. J. Psychiatry Med.
(1987)
T. De Mauro
Guida allùso delle parole
(1980)
M.W. Dysken et al.
Milacemide: a placebo-controlled study in the senile dementia of the Alzheimer type
J. Am. Geriatr. Soc.
(1992)

M. Farlow et al.

A controlled trial of tacrine in Alzheimer's disease

J. Am. Med. Assoc.

(1992)

Cited by (36)

Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer's disease
2009, Clinical Neurophysiology
Citation Excerpt :
As reported above, the long-term ibuprofen treatment did not affect global cognitive function as revealed by MMSE score. A first control analysis evaluated the effects of the ibuprofen treatment on another typical index of global cognitive function in elderly subjects, namely the total score of Alzheimer Disease Assessment Scale-cognitive (ADAS-cog Italian version, Fioravanti et al., 1994). Indeed, the total score of ADAS-cog is a typical endpoint of clinical trials on AD, since it probes the global severity of cognitive symptoms in AD (for review see: Birks, 2006; Birks and Flicker, 2006; Harrison, 2007; Wesnes, 2008).
Non-steroidal anti-inflammatory drugs such as ibuprofen have a protective role on risk of Alzheimer’s disease (AD). Here we evaluated the hypothesis that long-term ibuprofen treatment affects cortical sources of resting electroencephalographic (EEG) rhythms in mild AD patients.
Twenty-three AD patients (13 treated AD IBUPROFEN; 10 untreated AD PLACEBO) were enrolled. Resting EEG data were recorded before and 1 year after the ibuprofen/placebo treatment. EEG rhythms were delta (2–4 Hz), theta (4–8 Hz), alpha 1 (8–10.5 Hz), alpha 2 (10.5–13 Hz), beta 1 (13–20 Hz), and beta 2 (20–30 Hz). LORETA was used for EEG source analysis.
In the AD PLACEBO group, amplitude of delta sources was globally greater at follow-up than baseline. Instead, amplitude of delta sources remained stable or decreased in the majority of the AD IBUPROFEN patients. Clinical (CDR) but not global cognitive status (MMSE) reflected EEG results.
These results suggest that in mild AD patients, a long-term ibuprofen treatment slightly slows down the progressive increment of delta rhythms as a sign of contrast against the neurodegenerative processes.
They motivate future investigations with larger population and extended neuropsychological testing, to study the relationships among ibuprofen treatment, delta cortical sources, and higher order functions.
Vestibular rehabilitation in older adults with and without mild cognitive impairment: Effects of virtual reality using a head-mounted display
2019, Archives of Gerontology and Geriatrics
Citation Excerpt :
Vestibular testing parameters regarding twenty-three age-, gender- and education-matched UVH older adults with age-appropriate cognitive function were recruited from the Tor Vergata University Hospital database (Micarelli, Viziano, Della-Morte et al., 2018). The degree of dementia-related orientation behavior was also evaluated following the Alzheimer’s Disease Assessment Scale (ADAS-cog) orientation subscale in both groups (Fioravanti et al., 1994). According to accepted criteria (Hall et al., 2016), the diagnosis of chronic UVH was reached with at least 25% reduced vestibular response to bithermal water caloric irrigation on one side when calculated using the Jongkees’ formula (Alessandrini et al., 2014) at least 3 months after the beginning of symptoms.
Due to the gap in the knowledge in the field of vestibular rehabilitation the purpose of this randomized study is to highlight the outcomes of head-mounted display (HMD) implementation in older adults and patients with mild cognitive impairment (MCI), suffering from unilateral vestibular hypofunction (UVH).
Vestibulo-ocular reflex (VOR) gain, postural sway examination and dizziness-related and quality of life scores were collected in 12 UVH elderly and 12 UVH subjects suffering from MCI only undergoing vestibular rehabilitation and in 11 UVH elderly and 12 UVH subjects suffering from MCI undergoing a home-based HMD + vestibular rehabilitation protocol.
Although the within-subjects analysis found in all groups a significant (p < 0.05) improvement in posturography parameters and dizziness-related and quality of life scores and no changes in VOR gain, implementation of HMD demonstrated a significant (p < 0.05) increase in post-treatment between-group comparisons in the same tests and VOR gain with respect to those older adults and participants with MCI only undergoing vestibular rehabilitation. Positive correlations were discovered between Mini-Mental Score Exam values and pre-/post-treatment differences in (i) power spectra values in the low-frequency interval (r = 0.72) and in (ii) Dynamic Gait Index scores (r = 0.76).
This study demonstrates that the implementation of a home-based virtual reality protocol may be a safe option in order to ameliorate VOR, postural control and the quality of life also in the vestibular impaired patients in whom the presence of cognitive decline could hinder the achievement of the goal of rehabilitation.
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors
2010, International Psychogeriatrics
Mild parkinsonian signs and psycho-behavioral symptoms in subjects with mild cognitive impairment
2008, International Psychogeriatrics
Decreased Frontal Gamma Activity in Alzheimer Disease Patients
2022, Annals of Neurology
Health-Related Predictors of Changes in Cognitive Status in Community-Dwelling Older Individuals
2022, Frontiers in Aging Neuroscience

View all citing articles on Scopus

View full text

The Italian version of the Alzheimer's Disease Assessment Scale (ADAS): psychometric and normative characteristics from a normal aged population

Abstract

Biol. Psychiatry.

Brain Cog.

J. Psychiat. Res.

Biol. Psychiatry

Psychiatry Res.

Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer's disease: report of an open trial

Drug Dev. Res.

Pentoxifylline in cerebrovascular dementia

J. Am. Geriatr. Soc.

Comparison of two cognitive rating scales of medically ill patients

Int. J. Psychiatry Med.

Guida allùso delle parole

Milacemide: a placebo-controlled study in the senile dementia of the Alzheimer type

J. Am. Geriatr. Soc.

A controlled trial of tacrine in Alzheimer's disease

J. Am. Med. Assoc.